Edifice Health Trial Tests Supplement Formulas to Lower Inflammatory Age Score
A terminated RCT explored whether immunotype-targeted supplements could reduce iAge®, an AI-derived biomarker of chronic inflammation and immune aging.
Summary
Edifice Health launched a decentralized, double-blind, placebo-controlled trial to test whether personalized dietary supplements could lower iAge®, an AI-powered metric of inflammatory aging derived from immune phenotyping of a standard blood draw. The study targeted systemic chronic inflammation — a low-grade, persistent process distinct from acute inflammation that is thought to accelerate biological aging across otherwise healthy adults. Participants received immunotype-specific supplement formulations tailored to their immune profile rather than a one-size-fits-all product. The trial was ultimately terminated before completion, meaning no published results are available. Despite termination, the study represents an important early attempt to apply AI-derived biomarkers and personalized supplementation to the measurable reduction of inflammaging — one of the most discussed mechanisms underlying age-related decline.
Detailed Summary
Chronic low-grade inflammation, often called inflammaging, is increasingly recognized as a key driver of biological aging and age-related disease. Unlike acute inflammation triggered by infection or injury, this persistent immune activation quietly accelerates cellular and tissue decline over decades. Finding practical, measurable, and modifiable targets for this process is a central challenge of longevity medicine.
This study, registered by Edifice Health in 2021, attempted to address that challenge directly. The trial was a decentralized, double-blind, randomized, placebo-controlled investigation designed to test whether immunotype-specific dietary supplement formulations could reduce participants' iAge® scores. The iAge® metric is a proprietary biomarker calculated from blood-based immune phenotyping and AI algorithms, developed to quantify an individual's inflammatory age independently of their chronological age.
The intervention was notably personalized: rather than giving all participants the same supplement, the protocol matched formulations to each participant's immunotype — their distinctive immune system profile. This design reflects a broader trend toward precision supplementation, moving away from population-average dosing toward individually calibrated interventions.
The trial was terminated before completion, and no outcome data are publicly available. The reasons for termination have not been disclosed in the registry entry. This means no conclusions can be drawn about whether the supplements reduced iAge® or systemic chronic inflammation in the study population.
Despite this, the trial carries conceptual significance for the longevity field. It represents one of the first registered attempts to use an AI-derived immune aging biomarker as a primary trial endpoint, and to test personalized supplement regimens against that metric in a rigorous controlled design. Future trials using iAge® or similar immunological clocks as endpoints — if completed — could help validate both the biomarker's utility and the potential of targeted supplementation to meaningfully modify the pace of immune aging.
Key Findings
- Trial was terminated; no efficacy or safety results are publicly available from this study.
- iAge® uses AI and immune phenotyping from a standard blood draw to quantify inflammatory aging.
- Supplements were matched to individual immunotypes rather than given uniformly to all participants.
- Study targeted inflammaging in healthy ambulatory adults, not people with acute illness.
- This trial is among the first to use an AI-derived immune aging score as a clinical endpoint.
Methodology
The study was a decentralized, double-blind, randomized, placebo-controlled trial (Phase NA) assessing immunotype-specific dietary supplements versus placebo. Primary endpoints centered on changes in iAge® and systemic chronic inflammation markers. The trial was terminated prior to completion with no results posted.
Study Limitations
The trial was terminated before completion and no results data are publicly available, making any assessment of supplement efficacy impossible. The summary is based on the abstract and registry entry only; full protocol details, reasons for termination, and participant data are unavailable. iAge® itself remains a proprietary metric with limited independent validation in large prospective cohorts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.